Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Compass Pathways
Biotech
Compass delays phase 3 psychedelic data, lays off 30% of staff
With the trials overrunning by months, the biotech is laying off 30% of its employees—including some senior managers.
Nick Paul Taylor
Oct 31, 2024 9:00am
MBX Biosciences, MaaT Pharma and more—Chutes & Ladders
Jun 28, 2024 8:30am
Compass tracks PTSD improvements in midphase psilocybin trial
May 8, 2024 8:07am
Compass, Hackensack Meridian ink research deal for psilocybin
Jan 17, 2024 10:53am
Compass shows safety in first psilocybin trial for PTSD
Dec 20, 2023 7:26am
Data on psilocybin in anorexia point Compass to new opportunity
May 3, 2022 8:33am
